Cappella Medical Devices has initiated patient enrollment in a multi-centre, open-label Italian study, which will evaluate Sideguard stent for the treatment of coronary artery disease (CAD).

The study will assess the benefits of Sideguard stent as primary intervention, for managing bifurcation related coronary artery disease.

The Sideguard stent is designed to preserve the sidebranch of diseased coronary arteries by protecting the ostium, while minimising plaque shift.

Principal Investigator of the study, Giuseppe Massimo Sangiorgi said the shape and elastic properties of the nitinol Sideguard stent provide constant outward radial force on the lumen and ostium, providing support and protection to the side branch over time.